摘要
目的分析宁泌泰胶囊联合手术在慢性前列腺炎合并前列腺增生患者治疗中的应用价值。方法回顾性收集2019年6月至2022年6月聊城市第三人民医院收治的76例慢性前列腺炎合并前列腺增生患者临床资料,根据治疗方法不同分为两组,每组38例。观察组年龄(61.58±6.44)岁,对照组年龄(62.31±7.28)岁。均实施经尿道前列腺等离子电切术(PKRP),对照组给予常规治疗,观察组于对照组基础上加用宁泌泰胶囊。术前2周开始用药,并于手术后持续用药2周,共用药1个月。比较两组手术相关指标,治疗前、术前1 d及术后2周炎症指标[巨噬细胞炎性蛋白-1α(MIP-1α)、血管细胞黏附分子-1(VCAM-1)、白细胞介素-6(IL-6)]水平,治疗前、术前1 d及术后3个月尿流动力学指标[最大尿流率(Q_(max))、残余尿量(PVR)、膀胱稳定性]、慢性前列腺炎症状评分表(NIH-CPSI)评分、国际前列腺症状评分表(IPSS)评分。采用独立样本t检验、配对t检验。结果观察组手术时间、住院时间、术中出血量分别为(51.49±12.44)min、(5.19±0.98)d、(79.58±8.13)ml,对照组为(68.73±14.35)min、(6.08±1.22)d、(98.55±10.24)ml,差异均有统计学意义(t=5.596、3.506、8.944,均P<0.01)。观察组术前1 d血清MIP-1α、VCAM-1、IL-6水平分别为(14.95±2.18)µg/L、(72.58±8.51)ng/L、(185.73±32.62)ng/L,术后2周分别为(6.51±1.38)µg/L、(40.28±8.75)ng/L、(119.24±35.58)ng/L;对照组术前1 d为(16.83±2.27)µg/L、(81.44±8.22)ng/L、(215.37±31.11)ng/L,术后2周为(8.11±1.44)µg/L、(54.56±7.93)ng/L、(153.15±39.48)ng/L,差异均有统计学意义(t=3.682、4.616、4.053、4.945、7.454、3.993,均P<0.001)。观察组术后3个月Q_(max)、膀胱稳定性、PVR分别为(12.39±2.47)ml/s、(174.65±15.32)ml、(44.66±15.26)ml,对照组为(9.25±2.31)ml/s、(154.51±16.83)ml、(62.79±14.93)ml,差异均有统计学意义(t=5.724、5.455、5.235,均P<0.001)。观察组术前1 d、术后3个月NIH-CPSI评分分别为(17.17±2.11)分、(7.84±1.08)分,对照组为(19.16±2.15)分、(10.29±1.25)分(t=4.072、9.143,均P<0.001)。观察组术后3个月IPSS评分低于对照组[(8.17±1.43)分比(11.22±1.68)分](t=8.552,P<0.001)。结论宁泌泰胶囊联合PKRP治疗慢性前列腺炎合并前列腺增生,能减轻炎症反应,改善尿流动力学,有助于病情恢复。
Objective To analyze the application value of Ningbitai capsules combined with surgery in the treatment of chronic prostatitis(CP)with benign prostatic hyperplasia(BPH).Methods The clinical data of 76 patients with CP complicated with BPH admitted to Liaocheng Third People's Hospital from June 2019 to June 2022 were retrospectively collected,and they were divided into two groups according to different treatment methods,with 38 cases in each group.The observation group was(61.58±6.44)years old,and the control group was(62.31±7.28)years old.All patients underwent transurethral plasmakinetic resection of prostate(PKRP).The control group was given routine treatment,and the observation group was given Ningbitai capsules on the basis of the control group.The medication started 2 weeks before surgery and continued till 2 weeks after surgery,for a total of 1 month.The operation-related indexes,levels of inflammatory markers[macrophage inflammatory protein-1α(MIP-1α),vascular cell adhesion molecule-1(VCAM-1),and interleukin-6(IL-6)]before treatment,1 d before surgery,and 2 weeks after surgery,and urodynamic indexes[maximum urinary flow rate(Q_(max)),residual urine volume(PVR),and bladder stability],National Institutes of Health-Chronic Prostatitis Symptom Index(NIH-CPSI)scores,and International Prostatitis Symptom Scale(IPSS)scores before treatment,1 day before surgery,and 3 months after surgery were compared between the two groups.Independent sample t test and paired t test were used.Results The operation time,hospital stay,and intraoperative blood loss were(51.49±12.44)min,(5.19±0.98)days,and(79.58±8.13)ml in the observation group,and(68.73±14.35)min,(6.08±1.22)days,(98.55±10.24)ml in the control group,respectively,with statistically significant differences(t=5.596,3.506,and 8.944,all P<0.01).Serum MIP-1α,VCAM-1,and IL-6 levels in the observation group were(14.95±2.18)μg/L,(72.58±8.51)ng/L,and(185.73±32.62)ng/L 1 day before surgery,those were(6.51±1.38)μg/L,(40.28±8.75)ng/L,and(119.24±35.58)ng/L 2 weeks after surgery,and the results in the control group were(16.83±2.27)μg/L,(81.44±8.22)ng/L,and(215.37±31.11)ng/L 1 day before surgery and(8.11±1.44)μg/L,(54.56±7.93)ng/L,and(153.15±39.48)ng/L 2 weeks after surgery,with statistically significant differences(t=3.682,4.616,4.053,4.945,7.454,and 3.993,all P<0.001).The Qmax,bladder stability,and PVR in the observation group 3 months after surgery were(12.39±2.47)ml/s,(174.65±15.32)ml,and(44.66±15.26)ml,those in the control group were(9.25±2.31)ml/s,(154.51±16.83)ml,and(62.79±14.93)ml,with statistically significant differences(t=5.724,5.455,and 5.235,all P<0.001).The NIH-CPSI score of the observation group was(17.17±2.11)1 day before surgery and(7.84±1.08)points 3 months after surgery,while those of the control group were(19.16±2.15)and(10.29±1.25)points(t=4.072 and 9.143,both P<0.001).The IPSS score of the observation group was lower than that of the control group 3 months after surgery[(8.17±1.43)points vs.(11.22±1.68)points](t=8.552,P<0.001).Conclusion Ningbitai capsules combined with PKRP in the treatment of CP with BPH can reduce the inflammatory reaction,improve the urodynamics,and helps to recover.
作者
赵宗勇
任之尚
徐龙
刁统祥
Zhao Zongyong;Ren Zhishang;Xu Long;Diao Tongxiang(Department of Urology,Liaocheng Third People's Hospital,Liaocheng 252000,China;Department of Urology,Liaocheng Dongchangfu People's Hospital,Liaocheng 252000,China;Department of Urology,Provincial Hospital Affiliated to Shandong First Medical University,Jinan 250021,China)
出处
《国际医药卫生导报》
2023年第23期3407-3411,共5页
International Medicine and Health Guidance News
基金
山东省自然科学基金青年项目(zR2021QH366)。
关键词
慢性前列腺炎
前列腺增生
宁泌泰胶囊
尿流动力学
炎症指标
Chronic prostatitis
Benign prostatic hyperplasia
Ningbitai capsules
Urodynamics
Inflammation indexes
